Certain studies conducted in ovarian and lung cancer cell lines showed that the CXCR1/2 receptor/ligand pathway transactivates EGFR, promoting the downstream activation of MAPK signaling and mediating cell proliferation and survival (49,50). Here, EGFR is linked to lung carcinoma.